Targeted Network Meeting
Preclinical data: what makes preclinical data translatable?


 
coordinator: Thomas Steckler, Belgium
 
Wednesday 2 September 2015

08:00 - 15:00

D203
08:00 - 09:45 Robustness and generalisability
 chair: Thomas Steckler, Belgium
 
08:00 - 08:30Robustness and generalisability in the context of preclinical drug development
 speaker: Thomas Steckler, Belgium
 
08:30 - 09:00Generalisability to man: can we use comparable readouts preclinically and in patients?
 speaker: Martien Kas, Netherlands, The
 
09:00 - 09:30NIH’s efforts to assess generalisability – identifying the need to include female experimental subjects
 speaker: Elena Koustova, United States
 
09:30 - 09:45Discussion
 
09:45 - 10:15Break
 
10:15 - 12:00The utility of biomarkers to enhance robustness and generalisability preclinically and in the clinic
 chairs: t.b.a.,
 Gary Gilmour, United Kingdom
 
10:15 - 10:45Validating preclinical biomarkers in psychiatry - a mechanism-based approach
 speaker: Andreas Meyer-Lindenberg, Germany
 
10:45 - 11:15Pillars of success approach to predict success of proof-of-concept phase II studies
 speaker: t.b.a.
 
11:15 - 11:45Biomarker development from a quality perspective
 speaker: Lee Monk, United Kingdom
 
11:45 - 12:00Discussion
 
12:00 - 13:00Lunch
 
13:00 - 14:45Data sharing – current status and next steps
 chairs: Martin Michel, Germany
 Paul Moser, Portugal
 
13:00 - 13:30A proposal for a new data sharing mechanism for the preclinical data forum network
 speaker: Magali Haas, United States
 
13:30 - 14:00Data sharing in a public private partnership context: the innovative medicines initiative experience
 speaker: Elisabetta Vaudano, Belgium
 
14:00 - 14:30An update on European academic initiatives
 speaker: Malcolm McLeod, United Kingdom
 
14:30 - 14:45Discussion
 
14:45 - 15:00General discussion and closing